New research indicates that individuals who stop using new slimming jabs like semaglutide or tirzepatide may regain shed pounds far faster than those who halt traditional diet and exercise plans.
Findings released in a leading medical journal shows that while overweight people frequently drop substantial amounts of their body weight while using the jabs, the weight returns at an average rate of nearly a kilo each month once they quit.
"Users using such treatments should be aware of the risk of quick rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment mass within about a year and a half.
Weighing Therapies
The study, which looked at 37 of trials involving over 9,000 of participants, contrasted the effects of these new drugs with older methods.
The team point out that people who shed pounds through dieting typically experience a more gradual weight regain—approximately 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Doctors propose the way of the jabs is key to understanding the heightened rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal could lead to the system to produce less of its endogenous GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this medication means appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Condition?
The NHS suggest the injections for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, due to the high risk of weight regain, the therapy should be considered long-term.
This view is supported by drug manufacturers, who state that the results "highlight the chronic nature of obesity," similar to managing conditions like diabetes.
User Experiences
Users who have stopped the medication report a intense return of cravings.
"I experienced something activating and you become extremely hungry," recalled an individual.
This difficulty is worsened if users have not adopted permanent dietary or behavioural changes during treatment.
Widespread Use
Recent estimates suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, experts emphasize that while these medications are effective tools for shedding pounds, they are not a magic solution and lasting health benefits likely depends on ongoing behavioural changes.
